01412nas a2200265   4500000000100000008004100001260001300042653001200055653002400067653001500091653002300106653001600129653001100145653001200156653002400168653002500192653004200217653001400259245024300273856004100516300001000557490000700567520055800574022001401132       1995                            d  c1995 Mar10aAnimals10aAntigens, Bacterial10aArmadillos10aBacterial Vaccines10aGuinea Pigs10aHumans10aleprosy10aMycobacterium bovis10aMycobacterium leprae10aRandomized Controlled Trials as Topic10aVenezuela00aAnalysis of vaccines prepared from armadillo-derived M. leprae; results of an inter-laboratory study coordinated by the World Health Organization. Immunology of Mycobacterial Diseases (IMMYC) Steering Committee, World Health Organization.  uhttp://ila.ilsl.br/pdfs/v63n1a08.pdf  a48-550 v633 a<p>Preparations of armadillo-derived Mycobacterium leprae used in vaccine trials were analyzed using a combination of morphological, chemical and immunological criteria. When compared to more recent preparations, vaccine lots prepared in 1984 and 1985 were found to contain fewer intact bacilli and lower amounts of M. leprae antigens. These differences may be characteristic of the original preparations, or alternatively, may have arisen during prolonged storage. The early vaccine lots were those used in the recently published Venezuela trial.</p>
  a0148-916X